These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12072249)

  • 21. The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin.
    de Haan L; Verweij W; Agsteribbe E; Wilschut J
    Immunol Cell Biol; 1998 Jun; 76(3):270-9. PubMed ID: 9682971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highly efficient expression, purification of recombinant LTB protein and its activity against mucosal immunoadjuvant by nasal immunization.
    Wang J; Li L; Zheng J; Yu J; Yang X; Geng Y; Lai B; Wang Y; Si L
    Chin Med J (Engl); 2003 Jul; 116(7):1115-7. PubMed ID: 12890398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intranasal immunization of mice with recombinant Streptococcus gordonii expressing NadA of Neisseria meningitidis induces systemic bactericidal antibodies and local IgA.
    Ciabattini A; Giomarelli B; Parigi R; Chiavolini D; Pettini E; Aricò B; Giuliani MM; Santini L; Medaglini D; Pozzi G
    Vaccine; 2008 Aug; 26(33):4244-50. PubMed ID: 18582996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal immunization of BALB/c mice with enterotoxigenic Escherichia coli colonization factor CS6 encapsulated in biodegradable poly(DL-lactide-co-glycolide) microspheres.
    Byrd W; Cassels FJ
    Vaccine; 2006 Feb; 24(9):1359-66. PubMed ID: 16233937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction and immunogenicity evaluation of an epitope-based antigen against swine influenza A virus using Escherichia coli heat-labile toxin B subunit as a carrier-adjuvant.
    Sun Z; Lawson S; Langenhorst R; McCormick KL; Brunick C; Opriessnig T; Baker R; Yoon KJ; Zhang W; Huber VC; Fang Y
    Vet Microbiol; 2013 Jun; 164(3-4):229-38. PubMed ID: 23497910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal co-administration of recombinant active fragment of Zonula occludens toxin and truncated recombinant EspB triggers potent systemic, mucosal immune responses and reduces span of E. coli O157:H7 fecal shedding in BALB/c mice.
    Shekar A; Ramlal S; Jeyabalaji JK; Sripathy MH
    Med Microbiol Immunol; 2019 Feb; 208(1):89-100. PubMed ID: 30209565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI; Kurata T
    Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines.
    Baudner BC; Giuliani MM; Verhoef JC; Rappuoli R; Junginger HE; Giudice GD
    Vaccine; 2003 Sep; 21(25-26):3837-44. PubMed ID: 12922117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes.
    Park EJ; Chang JH; Kim JS; Yum JS; Chung SI
    Exp Mol Med; 2000 Jun; 32(2):72-8. PubMed ID: 10926118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Asanuma H; Tomita T; Komase K; Kawahara K; Danbara H; Hattori N; Watanabe K; Suzuki Y; Nagamine T
    Vaccine; 1994 Sep; 12(12):1083-9. PubMed ID: 7998417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants.
    Nawar HF; Arce S; Russell MW; Connell TD
    Infect Immun; 2007 Feb; 75(2):621-33. PubMed ID: 17118982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its vlosely related homologue, the B subunit of cholera toxin.
    Millar DG; Hirst TR; Snider DP
    Infect Immun; 2001 May; 69(5):3476-82. PubMed ID: 11292779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
    Stephenson I; Zambon MC; Rudin A; Colegate A; Podda A; Bugarini R; Del Giudice G; Minutello A; Bonnington S; Holmgren J; Mills KH; Nicholson KG
    J Virol; 2006 May; 80(10):4962-70. PubMed ID: 16641287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT).
    Cheng E; Cárdenas-Freytag L; Clements JD
    Vaccine; 1999 Aug; 18(1-2):38-49. PubMed ID: 10501233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo and in vitro adjuvant activities of the B subunit of Type IIb heat-labile enterotoxin (LT-IIb-B5) from Escherichia coli.
    Liang S; Hosur KB; Nawar HF; Russell MW; Connell TD; Hajishengallis G
    Vaccine; 2009 Jul; 27(32):4302-8. PubMed ID: 19450646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity.
    Haan L; Verweij WR; Holtrop M; Brands R; van Scharrenburg GJ; Palache AM; Agsteribbe E; Wilschut J
    Vaccine; 2001 Apr; 19(20-22):2898-907. PubMed ID: 11282201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant activity of a nontoxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strain.
    Guillobel HC; Carinhanha JI; Cárdenas L; Clements JD; de Almeida DF; Ferreira LC
    Infect Immun; 2000 Jul; 68(7):4349-53. PubMed ID: 10858258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli.
    Yu J; Cassels F; Scharton-Kersten T; Hammond SA; Hartman A; Angov E; Corthésy B; Alving C; Glenn G
    Infect Immun; 2002 Mar; 70(3):1056-68. PubMed ID: 11854183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant.
    Castagliuolo I; Sardina M; Brun P; DeRos C; Mastrotto C; Lovato L; Palù G
    Infect Immun; 2004 May; 72(5):2827-36. PubMed ID: 15102793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An adenovirus vectored mucosal adjuvant augments protection of mice immunized intranasally with an adenovirus-vectored foot-and-mouth disease virus subunit vaccine.
    Alejo DM; Moraes MP; Liao X; Dias CC; Tulman ER; Diaz-San Segundo F; Rood D; Grubman MJ; Silbart LK
    Vaccine; 2013 Apr; 31(18):2302-9. PubMed ID: 23499593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.